Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
HALO or FOLD: Which Is the Better Value Stock Right Now?
12:46pm, Monday, 23'rd Dec 2024
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two comp
NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act
01:09pm, Wednesday, 18'th Dec 2024
Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al.
Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension
03:28pm, Friday, 13'th Dec 2024
The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et al. The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
02:10pm, Friday, 13'th Dec 2024
Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settl
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy?
10:50am, Friday, 13'th Dec 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?
06:49am, Monday, 09'th Dec 2024
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
HALO vs. FOLD: Which Stock Is the Better Value Option?
12:41pm, Thursday, 05'th Dec 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two stocks is more attractive
NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial
01:14pm, Tuesday, 03'rd Dec 2024
Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al. Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al.
HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
12:40pm, Tuesday, 19'th Nov 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the
NCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial Rights
07:04pm, Tuesday, 12'th Nov 2024
Saul Ortega & David Rogers v. Office of the Comptroller of the Currency Saul Ortega & David Rogers v. Office of the Comptroller of the Currency
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated
11:40am, Thursday, 07'th Nov 2024
FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024.
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock
10:55am, Thursday, 07'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings
09:30pm, Wednesday, 06'th Nov 2024
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall
Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript
12:54pm, Wednesday, 06'th Nov 2024
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Marte
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates
09:25am, Wednesday, 06'th Nov 2024
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.07 per share a year ago.
